---
title: "New Stock Debut | \"First Stock of Innovative Kidney Disease Drugs\" ALEBUND-B Listed, Up Nearly 97% in Early Trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291079480.md"
description: "ALEBUND-B was listed on the Hong Kong stock market on its first day, with an issue price of HKD 22.6, raising a net amount of approximately HKD 1.181 billion. As the \"first stock of innovative drugs for kidney disease,\" its core product AP301 is a new drug for the treatment of hyperphosphatemia. In early trading, the stock price surged nearly 97%, and as of the time of writing, it has risen 95.22% to HKD 44.12, with a transaction volume of HKD 324 million"
datetime: "2026-06-29T01:54:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291079480.md)
  - [en](https://longbridge.com/en/news/291079480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291079480.md)
---

# New Stock Debut | "First Stock of Innovative Kidney Disease Drugs" ALEBUND-B Listed, Up Nearly 97% in Early Trading

According to Zhitong Finance APP, ALEBUND-B (09637) has officially listed, with the announcement showing a price of HKD 22.6 per share, a total issuance of 56.7554 million shares, and a minimum trading unit of 100 shares, with net proceeds of approximately HKD 1.181 billion. As of the time of writing, the stock has risen by 95.22%, trading at HKD 44.12, with a transaction volume of HKD 324 million.

Public information shows that ALEBUND is a biopharmaceutical company providing therapies for kidney diseases. According to data from ZhiShi Consulting, the company has the broadest range of candidate drugs for kidney indications globally. As of the last feasible date, the company's clinical and preclinical product portfolio consists of one core product, AP301, and six other candidate products, including: one late-stage clinical candidate (AP306), one preclinical candidate (AP303), and four preclinical candidates (AP308, AP304, AP305, and AP307).

Among them, the core product AP301 (which obtained all global rights from Vidasym in 2021) is classified as a new drug in China. AP301 is a phosphate binder used to treat hyperphosphatemia, one of the most common complications in CKD patients undergoing dialysis, with significant unmet medical needs. AP301 has completed Phase III registration clinical trials in China and is expected to submit a New Drug Application (NDA) shortly, with global Phase III pivotal multicenter clinical trials currently underway in the United States and China

### Related Stocks

- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)

## Related News & Research

- [Biotech Firms Push Weight-Loss and AI Pipelines Amid Buyback Wave](https://longbridge.com/en/news/291029476.md)
- [Beijing Biostar Wins Shareholder Backing for Capital Mandates and Governance Changes at AGM](https://longbridge.com/en/news/290979536.md)
- [Beijing Biostar Pharmaceuticals files directors list with Hong Kong exchange](https://longbridge.com/en/news/290974298.md)
- [China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds](https://longbridge.com/en/news/290965367.md)
- [Dr. Oz's GLP-1 Bridge could work, but it isn't a model for price controls](https://longbridge.com/en/news/291060486.md)